In this video, InMed Pharmaceuticals CEO Eric A. Adams speaks about the company’s ocular disease program. INM-088 is a cannabinol (CBN) formulation showing potential to reduce intraocular pressure and neuroprotection of the eye, important for glaucoma and several other eye diseases. InMed has conducted a number of preclinical studies of CBN, comparing it against several cannabinoids such as tetrahydrocannabinol (THC) and cannabidiol (CBD). CBN demonstrated the most optimal effect for glaucoma over other cannabinoids.
Peer-reviewed Publication: Rare phytocannabinoids exert anti-inflammatory effects on human keratinocytes via the endocannabinoid system and MAPK signalling pathway
A peer-reviewed scientific study entitled “Rare phytocannabinoids exert anti-inflammatory effects on human keratinocytes via the endocannabinoid system and MAPK signalling pathway” has been published in the International
March 13, 2023
